Kindeva Drug Delivery, a global contract development and manufacturing organization focused on drug-device combination products, has welcomed Denis Johnson to the company as its new Chief Operating Officer (COO).
 
Johnson joins Kindeva to lead global operations for all Kindeva’s manufacturing, research, and development facilities located across the U.S. and U.K.
 
As COO, he will be dedicated to global operations, but notably facilitating the expansion and opening of Kindeva’s new aseptic injectable fill-finish site in Bridgeton, Missouri, opening this year, as well as the company’s focus on bringing green propellants to commercial combination product manufacturing for more eco-friendly inhalers.
 
Johnson has extensive life sciences leadership and manufacturing experience to bring to this role. Most recently, he served as Head of Global Manufacturing and Technical Operations at Biogen and held several leadership roles at Catalent, Boston Scientific, Teradyne, and Johnson & Johnson.
 
He started his career in the U.S. Army managing logistics and operations.
 
“Denis’ extensive experience in the CDMO space and track record of driving operational excellence will be invaluable as Kindeva continues to expand and innovate in the drug-delivery space,” said Kindeva CEO Milton Boyer. “His strong leadership skills and deep understanding of the market will support Kindeva specifically in working toward introducing the first 152a commercial green propellant line to the market — clinical supply is already available and by 2025, we plan to introduce some of the first-ever products using this alternative propellant to the market. Additionally, Denis will focus on optimizing manufacturing processes, enhancing operational efficiencies, ensuring the highest level of quality and compliance across all facilities, and more.”
 
“Kindeva’s commitment to more patient-centric, sustainable drug delivery systems as well as continued growth, especially over the past year, is exciting,” said Johnson. “I’m excited to join the Kindeva team to drive continued operational excellence and implement strategies that ensure the timely delivery of life-changing medications to patients worldwide.”